Filgotinib demonstrates sustained clinical effectiveness and a favorable safety profile over 12 months in a real-world UC cohort with extensive prior biologic exposure. Effectiveness is optimized at earlier treatment lines, though meaningful benefit persists in heavily pre-treated populations.
Caballero-Mateos et al. (Mon,) studied this question.